Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
seizures
MedTech
Why now was the time for Ceribell’s upsized IPO
With its seizure-spotting brain monitor, Ceribell rang in a $180.3 million IPO last week and saw its stock price trade up about 47% after the launch.
Conor Hale
Oct 15, 2024 4:00pm
Seizure-spotting headset maker Ceribell seeks $101M Nasdaq IPO
Oct 7, 2024 11:30am
Praxis epilepsy drug reduces seizures in phase 2 trial
Sep 3, 2024 10:21am
Ovid halts preclinical work, IV program after soticlestat fail
Aug 13, 2024 9:15am
Stoke's Dravet syndrome med released of partial clinical hold
Aug 7, 2024 8:54am
Marinus lays off 20% to steady ship after IV seizure med issues
May 8, 2024 9:42am
